Tvardi shareholders back directors, pay and auditor
Tvardi Therapeutics, Inc. reported the voting results from its Annual Meeting of Stockholders held on June 9, 2026.
Rhea-AI Filing Summary
Tvardi Therapeutics, Inc. reported the voting results from its Annual Meeting of Stockholders held on June 9, 2026. Stockholders elected Imran Alibhai, Ph.D., Cynthia Smith and Sujal Shah as Class II directors to serve until the 2029 annual meeting.
They also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers and indicated a preference for holding this advisory vote every year. In addition, stockholders ratified the Audit Committee’s selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Votes for Imran Alibhai: 3,513,039 votes
Votes for Cynthia Smith: 3,392,877 votes
Votes for Sujal Shah: 3,507,652 votes
+3 more
6 metrics
Votes for Imran Alibhai
3,513,039 votes
Election as Class II director at 2026 annual meeting
Votes for Cynthia Smith
3,392,877 votes
Election as Class II director at 2026 annual meeting
Votes for Sujal Shah
3,507,652 votes
Election as Class II director at 2026 annual meeting
Say-on-pay support
3,482,265 votes for
Non-binding advisory vote on executive compensation
Say-on-frequency 1-year option
3,453,729 votes
Preferred frequency of advisory votes on compensation
Auditor ratification for votes
6,523,292 votes for
Ratification of Deloitte & Touche LLP for fiscal 2026
Key Terms
Annual Meeting of Stockholders, non-binding advisory basis, Broker Non-Votes, independent registered public accounting firm
4 terms
Annual Meeting of Stockholders regulatory
"On June 9, 2026, Tvardi Therapeutics, Inc. held its Annual Meeting of Stockholders"
non-binding advisory basis regulatory
"The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers"
A non-binding advisory basis is guidance or a recommendation offered for informational purposes that does not create legal obligations or guarantees; recipients can accept, modify, or ignore it without contractual consequences. Investors should treat it like a weather forecast for planning—useful for forming expectations and assessing risk, but not a firm promise—so they should verify assumptions, seek confirming information, and avoid relying on it as the sole basis for investment decisions.
Broker Non-Votes regulatory
"Broker Non-Votes 2,975,429"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm regulatory
"the Company of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Tvardi Therapeutics (TVRD) stockholders decide about board elections at the 2026 annual meeting?
Stockholders elected Imran Alibhai, Ph.D., Cynthia Smith and Sujal Shah as Class II directors. They will serve until the 2029 annual meeting and until their successors are elected or they resign or are removed earlier.
How did Tvardi Therapeutics (TVRD) vote on executive compensation in 2026?
Stockholders approved the compensation of Tvardi’s named executive officers on a non-binding advisory basis. The proposal received 3,482,265 votes for, 161,795 against, 16,451 abstentions, and 2,975,429 broker non-votes at the annual meeting.
What frequency of say-on-pay votes did Tvardi Therapeutics (TVRD) stockholders prefer?
Stockholders indicated a preference for an annual advisory vote on executive compensation. The one-year option received 3,453,729 votes, compared with 9,343 for two years, 15,435 for three years, and 182,004 abstentions, plus 2,975,429 broker non-votes.
How did Tvardi Therapeutics (TVRD) respond to the say-on-frequency vote outcome?
The company decided to hold future advisory votes on named executive officer compensation every year. This decision aligns with the Board’s recommendation and will remain in place until the next required advisory vote on say-on-pay frequency.
Which auditor did Tvardi Therapeutics (TVRD) stockholders ratify for fiscal 2026?
Stockholders ratified Deloitte & Touche LLP as Tvardi’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification received 6,523,292 votes for, 62,646 against, and 50,002 abstentions, with no broker non-votes reported.
Were there significant broker non-votes at Tvardi Therapeutics’ 2026 annual meeting?
Broker non-votes totaled 2,975,429 on the director elections, the advisory say-on-pay vote, and the say-on-frequency proposal. There were no broker non-votes reported on the auditor ratification proposal involving Deloitte & Touche LLP.
AI-generated analysis. How Rhea-AI works. Not financial advice.
